Xeris Biopharma Holdings Inc. (XERS)
$8.53
$-0.06
(-0.70%)
As on 04-Sep-2026 16:15EDT
Market cap
$1,555 Mln
Revenue (TTM)
$335 Mln
P/E Ratio
--
P/B Ratio
107.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-6.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
72.6
-
Debt to Equity
-19.4
-
Book Value
$-0.1
-
EPS
$-0.1
-
Face value
--
-
Shares outstanding
182,320,306
8 Years Aggregate
CFO
$-528.57 Mln
EBITDA
$-513.88 Mln
Net Profit
$-596.20 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Xeris Biopharma Holdings (XERS)
| 8.7 | 4.9 | 44.8 | 8.8 | 53.2 | 25.7 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Xeris Biopharma Holdings (XERS)
| 131.6 | 43.8 | 76.7 | -54.6 | -40.4 | -30.2 | -58.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Xeris Biopharma Holdings (XERS)
|
8.5 | 1,555.2 | 335.4 | -17.2 | 1.2 | -- | -- | 107.7 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Xeris Biopharma Holdings (XERS)
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for... the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Read more
-
Chairman & CEO
Mr. Paul R. Edick
-
Chairman & CEO
Mr. Paul R. Edick
-
Headquarters
Chicago, IL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Xeris Biopharma Holdings (XERS)
What is the current share price of Xeris Biopharma Holdings Inc (XERS) Today?
The share price of Xeris Biopharma Holdings Inc (XERS) is $8.53 (NASDAQ) as of 04-Sep-2026 16:15 EDT. Xeris Biopharma Holdings Inc (XERS) has given a return of 53.25% in the last 3 years.
What is the current PB & PE ratio of Xeris Biopharma Holdings Inc (XERS)?
Since, TTM earnings of Xeris Biopharma Holdings Inc (XERS) is negative, P/E ratio is not available.
The P/B ratio of Xeris Biopharma Holdings Inc (XERS) is 107.68 times as on 04-Sep-2026, a 1979 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
2,551.56 |
103.26 |
2024 |
-9.22 |
-17.07 |
2023 |
-5.21 |
-47.86 |
2022 |
-1.91 |
4.00 |
2021 |
-2.91 |
3.75 |
What is the 52 Week High and Low of Xeris Biopharma Holdings Inc (XERS)?
The 52-week high and low of Xeris Biopharma Holdings Inc (XERS) are Rs 10.08 and Rs 5.25 as of 06-Sep-2026.
What is the market cap of Xeris Biopharma Holdings Inc (XERS)?
Xeris Biopharma Holdings Inc (XERS) has a market capitalisation of $ 1,555 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Xeris Biopharma Holdings Inc (XERS)?
Before investing in Xeris Biopharma Holdings Inc (XERS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.